Penumbra (PEN) Peer Comparison
$318.29
$0.69
(0.22%)
As on 21-Sep-2026 15:43EDT
Market cap
$12,560 Mln
Revenue (TTM)
$1,505 Mln
P/E Ratio
78.2
P/B Ratio
8.2
Div. Yield
0 %
Edit
| Penumbra (PEN) | Avantor (AVTR) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
12,560 | 10,497 | 9,521 | 9,770 | 9,983 |
Revenue ($ Mln) |
1,505 | 6,561 | 613 | 2,589 | 785 |
Net Profit ($ Mln) |
160.59 | -578.00 | -188.05 | 222.40 | 41.54 |
Net Margin (%) |
10.67 | -8.81 | -30.68 | 8.59 | 5.29 |
RoE (%) |
10.86 | -10.33 | -28.10 | 3.04 | 1.97 |
Price to Earnings |
78.15 | -- | -- | 44.47 | 242.32 |
Price-To-Book |
8.19 | 1.91 | 14.13 | 1.36 | 4.76 |
Income Statement ($ Mln)
| Penumbra (PEN) | Avantor (AVTR) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1,504.87 | 6,561.10 | 612.84 | 2,589.30 | 785.10 |
|
Cost of Revenue
|
483.98 | 4,473.00 | 127.96 | 1,245.50 | 384.30 |
|
Gross Profit
|
942.44 | 2,139.40 | 393.22 | 1,343.60 | 347.62 |
|
Operating Expenses
|
833.56 | 2,373.70 | 565.37 | 1,108.90 | 335.50 |
|
Operating Profit (EBIT)
|
187.34 | -285.60 | -80.49 | 235.00 | 65.30 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
203.83 | -472.00 | -192.83 | 350.40 | 52.15 |
|
Provision for Tax
|
43.24 | 106.00 | -4.79 | 128.00 | 10.61 |
|
Profit after Tax (Net Income)
|
160.59 | -578.00 | -188.05 | 222.40 | 41.54 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
93.19 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Penumbra (PEN) | Avantor (AVTR) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
1,530.77 | 5,630.20 | 682.49 | 7,173.90 | 2,112.03 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
210.18 | 4,583.70 | 135.71 | 2,116.80 | 705.49 |
|
Current Liabilities
|
233.78 | 1,382.00 | 102.33 | 961.30 | 132.66 |
|
Total Liabilities
|
1,826.52 | 11,794.70 | 893.49 | 10,576.50 | 2,949.70 |
Assets ($ Mln)
| Penumbra (PEN) | Avantor (AVTR) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
630.60 | 9,133.70 | 404.74 | 7,231.50 | 1,749.63 |
|
Current Assets
|
1,344.12 | 2,462.20 | 515.78 | 3,020.50 | 1,200.55 |
|
Total Assets
|
1,826.52 | 11,794.70 | 893.49 | 10,576.50 | 2,949.70 |
|
Total Debt*
|
212.71 | 3,697.80 | 102.84 | 1,203.70 | 690.94 |
|
Net Current Assets
|
1,110.35 | 1,080.20 | 413.45 | 2,059.20 | 1,067.90 |
Cashflow ($ Mln)
| Penumbra (PEN) | Avantor (AVTR) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
238.66 | 623.80 | -46.34 | 532.20 | 117.42 |
|
Cash Flow from Investing Activities
|
-404.59 | -130.50 | -77.61 | -189.70 | -298.47 |
|
Cash from Financing Activities
|
26.53 | -409.40 | 11.89 | -283.20 | -15.21 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Penumbra (PEN) | Avantor (AVTR) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
11.76 | -5.43 | -22.53 | 8.98 | 1.79 |
|
ROE (%)
|
10.86 | -10.33 | -28.10 | 3.04 | 1.97 |
|
ROA (%)
|
7.95 | -4.08 | -18.00 | 2.02 | 1.36 |
|
EBIT Margin (%)
|
13.63 | -4.47 | -30.58 | -5.99 | 9.87 |
|
Net Margin (%)
|
10.67 | -8.81 | -30.68 | 8.59 | 5.29 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Penumbra (PEN) | Avantor (AVTR) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
17.55 | -1.57 | 41.55 | 1.37 | 16.49 |
|
EBIT Growth (%)
|
17.49 | -129.16 | -116.42 | -131.06 | 920.91 |
|
Net Profit Growth (%)
|
8.72 | -184.08 | -102.66 | -30.32 | 400.42 |
|
EPS Growth (%)
|
8.12 | -184.11 | -96.88 | -29.66 | 394.30 |
|
Book Value Growth (%)
|
17.33 | -9.82 | -12.65 | 2.19 | 2.16 |
Valuation Ratios
| Penumbra (PEN) | Avantor (AVTR) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
68.93 | -14.68 | -34.59 | -- | 189.42 |
|
Price / Book Value
|
8.58 | 1.40 | 9.90 | -- | 4.40 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
53.25 | 81.94 | -43.50 | -- | 55.90 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Penumbra (PEN) | Avantor (AVTR) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.65 | 0.00 | 0.11 | 0.26 |
|
Short term debt to equity ratio
|
0.01 | 0.01 | 0.00 | 0.06 | 0.01 |
|
Current Ratio
|
5.75 | 1.78 | 5.04 | 3.14 | 9.05 |
|
Quick Ratio
|
3.86 | 1.18 | 4.46 | 2.33 | 7.64 |
|
Interest Coverage
|
157.91 | -1.64 | -38.31 | 8.18 | 1.92 |
Operating Efficiency Ratios
| Penumbra (PEN) | Avantor (AVTR) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
12.65 | 17.36 | 22.67 | 17.06 | 20.09 |
|
Asset Turnover
|
0.74 | 0.46 | 0.59 | 0.24 | 0.26 |
|
Receivable days
|
46.54 | 58.79 | 60.95 | 65.39 | 72.41 |
|
Inventory Days
|
331.92 | 64.13 | 193.84 | 221.09 | 146.53 |
|
Payable days
|
26.16 | 58.13 | 60.19 | 37.02 | 29.05 |
|
Cash Conversion Cycle
|
352.30 | 64.79 | 194.60 | 249.46 | 189.88 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
